Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eiger Biopharma (NQ: EIGR )

10.73 USD +0.18 (+1.71%)
Official Closing Price Updated: 5:26 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Eiger Biopharma

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Mid-Morning Market Update: Markets Gain; Citigroup Earnings Top Estimates
Following the market opening Friday, the Dow traded up 0.18 percent to 21,571.42 while the NASDAQ climbed 0.20 percent to 6,287.06. The ... 
Tags GCBC EIGR DGICA
From Benzinga
Benzinga's Top Upgrades, Downgrades For July 14, 2017
Top Upgrades Analysts at JP Morgan upgraded Boeing Co (NYSE: BA) from Neutral to Overweight. Boeing shares rose 0.83 percent ... 
Tags BA MGLN Downgrades
From Benzinga
Sum Up The Pieces: VTWG Could Be Worth $136
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Premarket Biotech Digest – PFE receives EU approval, ALKS announces positive results, SRNE receives FDA approval
Pfizer Inc. announced receiving the European Commission’s approval for Besponsa treatment for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. 
Tags Stocks / Equities Pharma/Biotech Healthcare
From Blogs - TalkMarkets
BRIEF-Eiger BioPharma announces sale of non-strategic assets to Theragene Pharma
* Eiger BioPharmaceuticals announces sale of non-strategic assets to Theragene Pharmaceuticals 
Tags companyNews
From Reuters: Company News
Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), announced today an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology company, a non-strategic asset, Mydicar® (rAAV1-SERCA2a).... 
From PR Newswire
BRIEF-Eiger names David Apelian to board of directors
* Eiger announces appointment of biopharmaceutical industry veteran David Apelian, MD, PHD, MBA to its board of directors Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
- Company Prepares to Advance Orphan Disease Pipeline 
From PR Newswire
BRIEF-Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39
* Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients at american diabetes association meeting in san diego 
Tags companyNews
From Reuters: Company News
Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego
- Novel Liquid Formulation of Subcutaneous Exendin 9-39 Highlighted 
From PR Newswire
BRIEF-Eiger completes enrollments for phase 2 in hypoglycemia study
* Eiger completes enrollment in phase 2 multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1... 
Tags companyNews
From Reuters: Company News
Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced completion of enrollment of the Phase 2 multiple-ascending... 
From PR Newswire
Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger,... 
From PR Newswire
BRIEF-Eiger announces results of ubenimex and leukotriene b4 (LTB4) modulation in experimental lymphedema
* Eiger announces results demonstrating benefit of ubenimex and leukotriene B4 (LTB4) modulation in experimental lymphedema Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
- Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema 
From PR Newswire
BRIEF-Eiger Biopharmaceuticals says completes enrollment of phase 2 liberty study of ubenimex
* Eiger Biopharmaceuticals Inc says completes enrollment of phase 2 liberty study of ubenimex in pulmonary arterial hypertension Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
- Phase 2 LIBERTY Data Expected First Quarter 2018 
From PR Newswire
BRIEF-Eiger BioPharma Q1 loss per share $1.34
* Eiger biopharmaceuticals reports first quarter 2017 financial results 
Tags companyNews
From Reuters: Company News
Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results
- Five Phase 2 Programs in Four Orphan Indications Progressing 
From PR Newswire
Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced HDV/HBV co-infection prevalence data from an International Classification of Diseases (ICD) analysis presented at Digestive Disease Week... 
From PR Newswire
Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City
- Phase 2 LIBERTY Study Update for Ubenimex in PAH 
From PR Newswire
BRIEF-Eiger says filed U.S. IND for its treatment for HDV infection
* Eiger announces U.S. IND filing of pegylated interferon lambda for hepatitis delta virus infection Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com) 
Tags companyNews
From Reuters: Company News
Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling 
From PR Newswire
Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that an abstract describing prevalence of hepatitis delta virus (HDV) in the U.S. will be presented at Digestive Disease Week (DDW) in... 
From PR Newswire
BRIEF-Eiger announces additional phase 2 clinical trial results
* Eiger announces additional phase 2 clinical trial results for lonafarnib at the international liver congress 2017 
Tags companyNews
From Reuters: Company News
Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional supportive and encouraging lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program... 
From PR Newswire
Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
- Novel Liquid Formulation of Exendin 9-39 Advancing 
From PR Newswire
Analysts Forecast 13% Upside For IWO
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at the European... 
From PR Newswire
BRIEF-Eiger Biopharmaceuticals Q4 loss per share $1.53
* Eiger biopharmaceuticals reports fourth quarter and full year 2016 financial results 
Tags companyNews
From Reuters: Company News
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.